{"title":"白细胞介素-6 受体抑制的基因代型会增加患特应性皮炎的风险。","authors":"","doi":"10.1016/j.jaci.2024.05.016","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Dermatitis has been reported after initiation of IL-6 receptor (IL-6R) inhibitors (IL-6Ri), while genetic association studies of atopic dermatitis (AD) have implicated IL-6R pathway signaling. However, causality remains unclear. As the indications for IL-6Ri expand, so do the clinical importance of determining whether there is mechanistic evidence linking it to AD.</p></div><div><h3>Objective</h3><p>Our aim was to examine the association between IL-6Ri and risk of AD.</p></div><div><h3>Methods</h3><p>To genetically mimic IL-6Ri, we selected single-nucleotide polymorphisms within or near the <em>IL6R</em> gene associated with C-reactive protein at genome-wide significance among 343,524 individuals. Genetic data were obtained from 10,788 individuals with AD and 30,047 controls of European ancestry. We used inverse variance–weighted and pleiotropy-robust methods and examined genetic confounding using colocalization. Analyses were replicated by using 13,473 Finnish and 2,385 East Asian individuals with AD. The results from 3 independent analyses were pooled by meta-analysis.</p></div><div><h3>Results</h3><p>Genetically proxied IL-6Ri was associated with increased risk of AD (odds ratio [OR] = 1.78 per 4.4-mg/L reduction in C-reactive protein level [95% CI = 1.28-2.48] [<em>P</em> = 6.5 × 10<sup>–4</sup>]). The results were replicated using Finnish outcome data (OR = 2.07 [95% CI = 1.58-2.72] [<em>P</em> = 1.57 × 10<sup>–7</sup>]) and Eastern Asian data (OR = 1.68 [95% CI = 1.12-2.54] [<em>P</em> = .013]). Meta-analysis of 3 independent populations (OR = 1.89 [95% CI = 1.57-2.28] [<em>P</em> = 2.68 × 10<sup>–11</sup>]) showed no evidence of heterogeneity (<em>P</em> = .65). We found no statistical evidence for pleiotropy or genetic confounding.</p></div><div><h3>Conclusion</h3><p>This genetic investigation provides consistent evidence (across independent multiancestry populations) that IL-6R signaling is causally implicated in AD susceptibility. Clinicians should remain vigilant for adverse effects resembling AD when using IL-6R inhibitors for immune-mediated inflammatory diseases.</p></div>","PeriodicalId":14936,"journal":{"name":"Journal of Allergy and Clinical Immunology","volume":null,"pages":null},"PeriodicalIF":11.4000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0091674924005542/pdfft?md5=efed1153f3821123cc9119b507e66f45&pid=1-s2.0-S0091674924005542-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Genetically proxied IL-6 receptor inhibition is associated with increased risk of atopic dermatitis\",\"authors\":\"\",\"doi\":\"10.1016/j.jaci.2024.05.016\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Dermatitis has been reported after initiation of IL-6 receptor (IL-6R) inhibitors (IL-6Ri), while genetic association studies of atopic dermatitis (AD) have implicated IL-6R pathway signaling. However, causality remains unclear. As the indications for IL-6Ri expand, so do the clinical importance of determining whether there is mechanistic evidence linking it to AD.</p></div><div><h3>Objective</h3><p>Our aim was to examine the association between IL-6Ri and risk of AD.</p></div><div><h3>Methods</h3><p>To genetically mimic IL-6Ri, we selected single-nucleotide polymorphisms within or near the <em>IL6R</em> gene associated with C-reactive protein at genome-wide significance among 343,524 individuals. Genetic data were obtained from 10,788 individuals with AD and 30,047 controls of European ancestry. We used inverse variance–weighted and pleiotropy-robust methods and examined genetic confounding using colocalization. Analyses were replicated by using 13,473 Finnish and 2,385 East Asian individuals with AD. The results from 3 independent analyses were pooled by meta-analysis.</p></div><div><h3>Results</h3><p>Genetically proxied IL-6Ri was associated with increased risk of AD (odds ratio [OR] = 1.78 per 4.4-mg/L reduction in C-reactive protein level [95% CI = 1.28-2.48] [<em>P</em> = 6.5 × 10<sup>–4</sup>]). The results were replicated using Finnish outcome data (OR = 2.07 [95% CI = 1.58-2.72] [<em>P</em> = 1.57 × 10<sup>–7</sup>]) and Eastern Asian data (OR = 1.68 [95% CI = 1.12-2.54] [<em>P</em> = .013]). Meta-analysis of 3 independent populations (OR = 1.89 [95% CI = 1.57-2.28] [<em>P</em> = 2.68 × 10<sup>–11</sup>]) showed no evidence of heterogeneity (<em>P</em> = .65). We found no statistical evidence for pleiotropy or genetic confounding.</p></div><div><h3>Conclusion</h3><p>This genetic investigation provides consistent evidence (across independent multiancestry populations) that IL-6R signaling is causally implicated in AD susceptibility. Clinicians should remain vigilant for adverse effects resembling AD when using IL-6R inhibitors for immune-mediated inflammatory diseases.</p></div>\",\"PeriodicalId\":14936,\"journal\":{\"name\":\"Journal of Allergy and Clinical Immunology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":11.4000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0091674924005542/pdfft?md5=efed1153f3821123cc9119b507e66f45&pid=1-s2.0-S0091674924005542-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Allergy and Clinical Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0091674924005542\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Allergy and Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0091674924005542","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:据报道,开始使用 IL-6 受体抑制剂(IL-6Ri)后会出现皮炎,而特应性皮炎(AD)的遗传关联研究与 IL-6R 通路信号有关。然而,因果关系仍不明确。随着IL-6Ri适应症的扩大,确定IL-6Ri是否与特应性皮炎有机理关联的临床重要性也在增加:研究 IL-6Ri 与 AD 风险之间的关联:为了在基因上模拟 IL-6Ri,我们在 343524 人中选择了与 C 反应蛋白(CRP)相关的 IL6R 基因内或附近的单核苷酸多态性,这些多态性在全基因组范围内具有重要意义。我们从 10,788 例病例和 30,047 例欧洲血统的对照组中获得了注意力缺失症的基因数据。我们使用了反方差加权法和多向性稳健法,并使用共定位法检验了遗传混杂因素。我们使用 13,473 例AD 芬兰病例和 2,385 例东亚病例进行了重复分析。通过荟萃分析对三项独立分析的结果进行了汇总:结果:IL-6Ri基因代偿与AD风险增加有关(CRP每降低4.4毫克/升,OR为1.78;95%CI为1.28,2.48;p=6.5x10-4)。芬兰的结果数据(OR 2.07;95%CI 1.58,2.72;p=1.57x10-7)和东亚数据集(OR 1.68;95%CI 1.12,2.54;p=0.013)重复了这一结果。对三个独立人群的 Meta 分析(OR 1.89;95%CI 1.57,2.28;p=2.68x10-11)显示没有异质性的统计学证据(p=0.65)。我们没有发现多效性或遗传混杂的统计学证据:这项基因调查在独立的多种族人群中提供了一致的证据,表明 IL-6R 信号与 AD 易感性有因果关系。临床医生在使用IL-6R抑制剂治疗免疫介导的炎症性疾病时,应继续警惕类似AD的不良反应。
Genetically proxied IL-6 receptor inhibition is associated with increased risk of atopic dermatitis
Background
Dermatitis has been reported after initiation of IL-6 receptor (IL-6R) inhibitors (IL-6Ri), while genetic association studies of atopic dermatitis (AD) have implicated IL-6R pathway signaling. However, causality remains unclear. As the indications for IL-6Ri expand, so do the clinical importance of determining whether there is mechanistic evidence linking it to AD.
Objective
Our aim was to examine the association between IL-6Ri and risk of AD.
Methods
To genetically mimic IL-6Ri, we selected single-nucleotide polymorphisms within or near the IL6R gene associated with C-reactive protein at genome-wide significance among 343,524 individuals. Genetic data were obtained from 10,788 individuals with AD and 30,047 controls of European ancestry. We used inverse variance–weighted and pleiotropy-robust methods and examined genetic confounding using colocalization. Analyses were replicated by using 13,473 Finnish and 2,385 East Asian individuals with AD. The results from 3 independent analyses were pooled by meta-analysis.
Results
Genetically proxied IL-6Ri was associated with increased risk of AD (odds ratio [OR] = 1.78 per 4.4-mg/L reduction in C-reactive protein level [95% CI = 1.28-2.48] [P = 6.5 × 10–4]). The results were replicated using Finnish outcome data (OR = 2.07 [95% CI = 1.58-2.72] [P = 1.57 × 10–7]) and Eastern Asian data (OR = 1.68 [95% CI = 1.12-2.54] [P = .013]). Meta-analysis of 3 independent populations (OR = 1.89 [95% CI = 1.57-2.28] [P = 2.68 × 10–11]) showed no evidence of heterogeneity (P = .65). We found no statistical evidence for pleiotropy or genetic confounding.
Conclusion
This genetic investigation provides consistent evidence (across independent multiancestry populations) that IL-6R signaling is causally implicated in AD susceptibility. Clinicians should remain vigilant for adverse effects resembling AD when using IL-6R inhibitors for immune-mediated inflammatory diseases.
期刊介绍:
The Journal of Allergy and Clinical Immunology is a prestigious publication that features groundbreaking research in the fields of Allergy, Asthma, and Immunology. This influential journal publishes high-impact research papers that explore various topics, including asthma, food allergy, allergic rhinitis, atopic dermatitis, primary immune deficiencies, occupational and environmental allergy, and other allergic and immunologic diseases. The articles not only report on clinical trials and mechanistic studies but also provide insights into novel therapies, underlying mechanisms, and important discoveries that contribute to our understanding of these diseases. By sharing this valuable information, the journal aims to enhance the diagnosis and management of patients in the future.